CALQUENCE (AstraZeneca Pty Ltd)
Product name
CALQUENCE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
35 working days (255)
Active ingredients
acalabrutinib
Registration type
NCE/NBE
Indication
CALQUENCE (capsules) is indicated for the treatment of patients with chronic lymphocytic leukaemia(CLL)/small lymphocytic lymphoma (SLL).